ArticleSports medicine - open2026
Evaluation of GFAP, UCH-L1 and S100B Blood Biomarkers for the Management of Sports-Related Concussion in Professional Rugby Players: A Prospective Observational Study.
Article in Sports medicine - open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe incidence of sports-related concussion (SRC) in rugby has been rising in recent years. The Head Injury Assessment (HIA) protocol, used to manage SRC, is limited by its reliance on subjective symptom reporting. Blood biomarkers such as glial fibrillary acidic protein (GFAP), ubiquitin C-terminal hydrolase L1 (UCH-L1) and S100B could serve as complementary objective tools for SRC management.
resultsA prospective cohort study was conducted in a French elite professional rugby team (Association Montferrandaise Clermont Auvergne Sports, Association Sportive Montferrandaise Clermont Auvergne). A total of 68 professional rugby players were followed from September 2022 to June 2024. During this study period, 23 SRC episodes with blood samples collected according to the HIA protocol were included. S100B baseline levels remained stable across the season in control players. For GFAP and UCH-L1, all baseline values were consistently below the measurable range limits (GFAP < 30 ng/L and UCH-L1 < 200 ng/L). At 2 h post-match (in the absence of SRC), both S100B and UCH-L1 levels increased significantly and were positively correlated with contact frequency, whereas GFAP levels showed no significant change at this early timepoint. At the 36-h post-match follow-up, concentrations of all three biomarkers had returned to baseline, supporting the use of this timepoint within the validated HIA protocol. At 36 h following SRC, UCH-L1 concentrations remained below the quantifiable range, suggesting that earlier sampling may be required to capture post-injury changes for this biomarker. At this timepoint, an increase in S100B of ≥ 15% from baseline yielded 100% specificity (SP) and 39% sensitivity (SE) for SRC diagnosis. Elevated GFAP concentrations (≥30 ng/L) were observed in some players with SRC, providing 100% SP and 17% SE. Combining S100B and GFAP maintained 100% SP while improving SE to 52%.
conclusionAt 36 h post-match, both GFAP and S100B demonstrated 100% SP for the diagnosis of SRC in professional rugby players. Their integration into routine HIA assessments may offer objective support to clinical decision-making and help enhance player safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.